The Expert Committee recommended the addition of a note to the listing of diazepam in this section of the EML to indicate use is only recommended for the short-term emergency management of acute and severe anxiety symptoms as the balance of benefits and risks of diazepam use under these circumstances is considered favourable. The Committee also recommended that lorazepam should be specified as the only therapeutic alternative under the square box listing for diazepam for this indication. These recommendations are aligned with expected recommendations in updated mhGAP guidelines.